In non-small cell, non-squamous lung cancer, endothelial growth factor receptor (EGFR) mutations are present in 20 % and anaplastic lymphoma kinase (ALK) rearrangements are present in 3–5 % of cases. This evidence concerns the gene ALK and non-small cell squamous lung carcinoma.